To characterize the expression of fibroblast growth factor binding protein (FGF-BP) messenger RNA (mRNA) in head and neck squamous cell carcinoma (HNSCC) and to study the association of FGF-BP with vascularity.
H
EAD AND NECK SQUAmous cell carcinoma (HNSCC) is the sixth most common tumor in humans 1 ; it is a solid tumor and heavily dependent on angiogenesis. 2 One of the angiogenic mechanisms for tumors relies on the recruitment and utilization of locally stored fibroblast growth factors (FGFs). 3 It is known that FGFs are involved in angiogenesis 4 and neoplasia, 5 and FGF binding protein (FGF-BP) has been detected in several HNSCC cell lines and tissues. 3 However, whether FGF-BP is extensively expressed in HNSCC tissues and plays a role in the angiogenesis of HNSCC remains to be elucidated.
A secreted protein, FGF-BP binds to acidic and basic FGFs in a noncovalent reversible manner. 6, 7 It was originally isolated from human epidermoid carcinoma cells. 8 The expression of FGF-BP is downregulated in normal adult tissues but upregulated in skin cancer. 9 Overexpression or, conversely, reduced expression of FGF-BP has indicated a role in the angiogenesis of tumors. 4 Expression of the mouse FGF-BP gene was found to be prominent in the skin and intestine during the prenatal phase but is downregulated in adult mice. 9 The expression of FGF-BP was reported to facilitate a nontumorigenic-to-tumorigenic switch in a human cell line (SW-13). 3 Expression of FGF-BP in these cells recruits basic FGF from the extracellular storage and allows it to reach the FGF receptor. 4, 10 Nuclear factor B (NF-B) is highly active in the angiogenesis of tumors. It is known that NF-B binds to the promoter of interleukin 8 (IL-8), vascular endothelial growth factor (VEGF), and cyclooxygenase 2 (COX-2) and thus increases the transcription of these angiogenic factors. 11 We hypothesized for this study that FGF-BP is related to the angiogenesis of HNSCC and used cellular methods to in-vestigate FGF-BP expression in HNSCC specimens. The correlates between FGF-BP and NF-B as well as FGF-BP and microvessel counts were evaluated by statistical analysis.
METHODS
Thirty-five primary HNSCC specimens, 8 metastatic tumor specimens, and 7 histologically adjacent control tissues were procured from 42 patients treated surgically at the University of Minnesota Hospitals and Clinics (UMHC). All specimens and clinical data in this study were procured, handled, and maintained according to the protocols approved by the institutional review board at the University of Minnesota. Of the patients with primary HNSCC, 28 were men, and 7 were women; mean (SD) age was 63.8 (12.6) years (age range, 36-93 years ). Eight tumors were located in the larynx, 4 in the pharynx, 11 in the oral cavity, 3 in the nasal cavity, 4 on the face, and 5 in the neck. Histologically, there were 4 well-differentiated SCCs, 20 moderately differentiated SCCs, and 11 poorly differentiated SCCs.
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
Head and neck SCC specimens (approximately 0.5-1.0 g of tissue per specimen) were obtained from surgical resections. In the operating room, the tissues were immediately frozen in liquid nitrogen and homogenized in a solution of 5M guanidine isothiocyanate, 0.5% sarcosyl, 25mM sodium citrate (pH 7.0), and 0.1M 2-mercaptoethanol. Total cellular RNA was isolated by extraction with guanidium thiocyanate-acidic-phenolchloroform, as previously described. 12 The primer sequences used to amplify FGF-BP complementary DNA (cDNA) were designed based on the cDNA sequence published in GenBank. Primer 1, sense mutations, included 98 to 120 base pairs (bp); primer 2, antisense, 777 to 799 bp; primer 3, sense, 209-232 bp; and primer 4, antisense, 546-568 bp.
Total RNA was reverse transcribed in a volume of 50 µL using GeneAmp RNA PCR Core Kit (Roche Molecular Systems Inc, Branchburg, New Jersey) according to the manufacturer's instructions. Polymerase chain reaction was performed as previously described 13 using primer pair combinations 1ϩ2, 1ϩ4, 3ϩ2, and 3ϩ4. The RT-PCR reaction generated 4 fragments, and 1 of the fragments was 702 bp long.
SUBCLONING
Polymerase chain reaction products underwent electrophoresis in 1% agarose gel. They were then dissected out, purified using a PCR product clean kit (Promega Corporation, Madison, Wisconsin), cut with EcoRI endonuclease (Promega Corporation), and cloned into the multiple cloning site of a plasmid (pBluescript II vector; Stratagene, La Jolla, California). The plasmid was amplified with Escherichia coli, extracted using a MAXprep Kit (Promega), sequenced, and compared with the original sequence using BLAST software, version 2.0.6 (National Center for Biotechnology Information; http://www.ncbi .nlm.nih.gov). The 702-bp fragment in the pBluescript II was used as a template for making sense and antisense probes for in situ hybridization.
IN SITU HYBRIDIZATION
In situ hybridization was performed as previously described. 14 Briefly, FGF-BP cDNA from the plasmid was reverse transcribed into mRNA transcripts with DNA-dependent RNA polymerase using T7/T3 promoters. Both sense and antisense riboprobes with sulfur 35 ( 35 S) radiolabels were prepared using the MAXIscript In vitro Transcription Kit (Applied Biosystems/ Ambion, Austin, Texas). The antisense riboprobe was used for hybridization and the sense riboprobe used as a control. Paraffinembedded specimens were cut and deparaffinized with xylene and graded ethanol solutions. Slides were pretreated with digitonin, digested with proteinase K, acetylated with acetic anhydride, dehydrated through graded ethanol solutions, and hybridized with 10 5 counts per minute per microgram of 35 S riboprobes. Slides were stringently washed, digested with ribonucleases A and T1, dehydrated with graded ethanol solutions, coated with film emulsion (Eastman Kodak, Rochester, New York), exposed for 24 hours, counterstained with hematoxylin-eosin, and documented microscopically.
IMMUNOHISTOCHEMICAL ANALYSIS AND MICROVESSEL QUANTITATION
To identify microvessels in tumor specimens, immunohistochemical analysis was performed by using specific antibodies against von Willebrand factor (vWF), 1:25 dilution Dako North America Inc, Carpinteria, California) and/or CD34, 1:50 dilution (Zymed Laboratories Inc, Carlsbad, California) routinely on the 35 primary HNSCC specimens. Nonspecific IgG was used for a control. Slides were examined under a microscope at low power (original magnification ϫ40) for identification of the region rich in blood vessels. Five highly vascularized areas within the tumor mass for each slide were taken for microvessel counting. In each of these specimens, 5 areas found to be positive for vWF and/or CD34 were counted under a microscope with original magnification ϫ100 added, and averaged. To clearly see the microvessel details, photographs were taken at original magnifications ϫ100, ϫ200, and ϫ400. Large vessels with thick muscular walls or with lumens greater than 50 µm were excluded from the count. Results were expressed as the average number of microvessels identified within 10 consecutive high-power fields, as previously described. 15 For cultured cell immunohistochemical analysis, we used specific antibodies against NF-B subunit p65 from Abcam (Cambridge, Massachusetts), 1:100 dilution (ab7970), and a secondary antibody fluorescein isothiocyanate conjugated to green.
STATISTICAL ANALYSIS
We used the 2 test to evaluate correlates between NF-B expression intensities and FGF-BP levels. The Spearman rank correlation was used to evaluate correlates between FGF-BP expression levels and microvessel counts. The method was chosen because of the nondeterminant associations (positive or negative) between FGF-BP and microvessel counts. Significance was set at PϽ.05.
RESULTS

EXPRESSION OF FGF-BP IN HNSCC
Four overlapping cDNA fragments encoding SCC FGF-BP were isolated by RT-PCR using the FGF-BP primer combinations. The amplified RT-PCR products from HNSCC specimens using 4 sets of primer pairs are schematically presented in Figure 1A . Using these primer pairs, the PCR products amplified from 3 individual HNSCC specimens were obtained ( Figure 1B, lanes 1-12) . The RT-PCR product was not observed when the mRNA sample was omitted ( Figure 1B, lane 13) . The PCR products in Figure 1B were sequenced and matched to the sequence of FGF-BP originally from epidermoid carcinoma by a nucleotide BLAST-searching tool on the National Institutes of Health Web site (http://www.ncbi.nlm.nih .gov/). To localize the expression site of FGF-BP in HNSCC specimens, in situ hybridization on all the tissue specimens (HNSSC and control tissues) was performed. The representative results for FGF-BP in situ hybridization are presented in Figure 1C -E: the sense riboprobe for FGF-BP, Figure 1C , and antisense riboprobe for FGF-BP (with 2 different magnifications, Figure 1D and E). Note that FGF-BP is frequently expressed at the edge of tumor lumps ( Figure 1E ).
In the in situ hybridization experiment, there were no detectable FGF-BP signals in the normal adult larynx (Figure 2A) , tongue, and lymph node. Of the 35 primary HNSCC specimens, no signals were found in 1; weak to medium signals were found in 18 ( Figure 2B and C); and strong signals were found in 16 ( Figure 2D ). The profile of FGF-BP mRNA transcripts in 35 primary HNSCC tumors by in situ hybridization is summarized in Figure 2E . In the metastatic cases, the expression of FGF-BP mRNA transcripts was examined in 8 lymph nodes and soft tissues containing metastatic HNSCC cells. Strong signals were found in 3 of the 8; weak to medium signals in 2; and no signals in 3 ( Figure 2F ). In FGF-BP highly expressed specimens, there was apparent NF-B expression. No signals were detected when a sense riboprobe for FGF-BP was used for hybridization with HNSCC sections.
ASSOCIATION OF FGF-BP EXPRESSION WITH NF-B IN HNSCC
To study the correlation between FGF-BP and NF-B expression, we evaluated NF-B expression in 35 primary HNSCC specimens. Among 16 FGF-BP highly expressed specimens and 18 FGF-BP weakly to moderately expressed specimens, NF-B expression was evaluated by immunohistochemical analysis. Two independent observers blindly evaluated the expression of FGF-BP and NF-B. It was found that there was an association between FGF-BP expression and NF-B levels ( Table 1) . Statistical analysis using the 2 test showed P Ͻ .05 (Minitab software, version 15; Minitab Inc, State College, Pennsylvania).
CORRELATION BETWEEN MICROVESSEL COUNTS AND FGF-BP EXPRESSION
No specific staining was observed in the immunohistochemical controls when anti-vWF and anti-CD34 antibodies were replaced by a nonspecific IgG (sc-2709; Santa Cruz A, Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using primer pairs indicated in (not scaled for the schematic bars, box, and arrows). B, Individual RT-PCR products from 3 HNSCC specimens (lanes 1-4, the products from specimen 1; lanes 5-8, the products from specimen 2; and lanes 9-12, the products from specimen 3); lane 13 represents the PCR negative control (ctrl). C-E, By in situ hybridization, the FGF-BP mRNA transcript signals were not detected when the control sense riboprobe was used (C) (original magnification ϫ40), whereas the signals were detected when the antisense riboprobe was used (D, original magnification ϫ40; E, original magnification ϫ200). The FGF-BP mRNA transcript signals are located at the edge of tumor lumps.
Biotechnology Inc, Santa Cruz, California). Frequently, the highest density of microvessels was observed at the invasive edge of tumors where the expression of NF-B was also high (data not shown). Microvessels were identified from HNSCC specimens by immunohistochemical stain on the tissue sections with antiendothelial cell marker antibodies, namely anti-vWF and anti-CD34 antibodies (Figure 3) . Microvessel counts in 35 HNSCC specimens ranged from 26 to 134 with a mean (SD) of 57 (24) for vWF and CD34 staining when viewed under a microscope at a low-power field (original magnification ϫ100). There was no statistically significant association between vessel counts and age, sex, or cancer stage (data not shown). However, the vessel counts were significantly higher in patients with metastatic tumors (lymphatic node metastasis or protrusions into the neighborhood) than in those without metastatic tumors (PϽ.05).
There was a close correlation between the microvessel density and FGF-BP expression in primary HNSCC tumors (PϽ.001 using the Spearman test). In tumors with microvessel counts of more than 60 per low-power field, 84.4% of samples were highly positive for FGF-BP. The mean (SD) microvessel counts in highly FGF-BPpositive HNSCC specimens (61 [24]) were significantly higher (PϽ.001) than in weakly to moderately FGF-BPpositive tumors (40 [13] ). Correlates between microvessel counts and FGF-BP expression levels are summarized in Table 2 .
COMMENT
In this study we found that FGF-BP is extensively expressed in primary HNSCC tumors and some metastatic cells but not in normal adult mucosal tissues. This is consistent with the findings of Czubayko et al 3 that FGF-BP was expressed in 9 of 11 HNSCC specimens. Fibroblast growth factor binding protein cDNA was isolated from HNSCC specimens with its sequence matched to that in the A431 human epidermoid carcinoma cells. 
